Building Clinical Trials Capacity for Tuberculosis Drugs in High-Burden Countries
(2007; 4 pages)

Abstract

The standard preferred regimen for the treatment of drug-susceptible tuberculosis (TB) around the world consists of a two-month induction phase of isoniazid, rifampin, pyrazinamide, and ethambutol followed by a continuation phase of four months of isoniazid and rifampin. This regimen has several advantages:

  1. it is essentially completely effective in achieving sputum culture conversion;
  2. it is relatively inexpensive and universally available;
  3. the relapse rate is low, at 3%–5%; and
  4. it can be administered largely intermittently. But the regimen has significant limitations.

These limitations can only be overcome by building TB clinical trials capacity.

 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 1, 2019